Skip to main content
. 2022 Feb 24;9:817453. doi: 10.3389/fcvm.2022.817453

Table 2.

Primary and secondary endpoint of the current study.

Outcome Novel device (n = 102) Control (n = 102) P-value
Primary endpoint, n (%)
Grade 1 hematoma 8 (7.8) 24 (23.5) <0.01
Grade 2 hematoma 2 (2.0) 6 (5.9) <0.01
Grade 3 hematoma 2 (2.0) 7 (6.8) 0.03
Secondary endpoint
Skin erosions, n (%) 0 (0) 9 (8.8) <0.01
Patient comfort score, mean ± SD 7.2 ± 1.1 4.8± 0.8 <0.01